Financials

  • Market Capitalization 13.69 B
  • Employee 1 077
  • Founded 1994
  • CEO Michael M. Morrissey
  • Website www.exelixis.com
  • Headquarter Delaware, United States
  • FIGI BBG000BQ4WF8
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
15.68
Price to sales ratio
5.29

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
696
ASND
Ascendis Pharma A/S - American Depositary Shares
249.36 USD-0.36%-2.48%-2.19%+21.59%15.45 B USD
700
BBIO
BridgeBio Pharma, Inc. - Common Stock
78.68 USD-0.87%-5.08%-7.02%+38.04%15.38 B USD
802
BMRN
BioMarin Pharmaceutical Inc. - Common Stock
65.29 USD-0.49%-3.35%+5.19%+13.47%12.64 B USD
803
CORT
Corcept Therapeutics Incorporated - Common Stock
116.93 USD-2.40%-3.75%+23.08%+59.37%12.64 B USD

Frequently asked questions about Exelixis Inc

What is the Exelixis Inc stock price today?

The current price of Exelixis Inc (EXEL) is 55.26. Over the past 24 hours, the stock has changed by -1.50%. Follow the EXEL chart for real-time price dynamics.

What is the stock ticker of Exelixis Inc?

Exelixis Inc trades under the ticker EXEL. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Exelixis Inc stock going up?

EXEL has changed by +2.83% over the last week, -2.11% over the last month, and +41.55% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Exelixis Inc?

Exelixis Inc currently has a market capitalization of 13.69 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Exelixis Inc earnings last quarter?

Last quarter, Exelixis Inc reported earnings of 0.85 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Exelixis Inc revenue for the last quarter?

Exelixis Inc reported quarterly revenue of 628.69 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Exelixis Inc net income for the last quarter?

Exelixis Inc reported net income of 212.05 M for the last quarter. The previous quarter showed 210.47 M, which means net income changed by +0.75%.

How many employees does Exelixis Inc have?

As of the latest available data, Exelixis Inc has 1 077 employees. Workforce size can provide additional context about the company's scale and operations.

What is Exelixis Inc EBITDA?

Exelixis Inc EBITDA is 255.4 M, and its EBITDA margin is 40.62%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Exelixis Inc stock?

You can buy Exelixis Inc (EXEL) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Exelixis Inc stock?

Investing in Exelixis Inc requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the EXEL chart and related analysis on metatrader.com as part of your research.

Exelixis, Inc. - Common Stock

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

News